巴西背景下 CAR-T 疗法开发的监管格局

INTRODUCTION: Chimeric antigen receptor T (CAR-T) therapy represents a significant advance in the treatment of hematologic malignancies, yet its global implementation remains limited by regulatory, logistical, and manufacturing challenges. Understanding differences among international regulatory frameworks is essential for expanding safe and equitable access, particularly in emerging academic programs. AREAS COVERED: This review examines the regulatory pathways, manufacturing requirements, and quality standards governing CAR-T therapies in Brazil, comparing them with those in the United States and the European Union.

A focused literature search encompassed peer-reviewed articles, institutional guidelines, and regulatory documents from 2016 to 2025. Key elements assessed include GMP expectations, analytical method validation, biosafety considerations, and infrastructure requirements.

The analysis also explores expanded-access mechanisms and summarizes clinical experiences that have used these pathways in the real world. EXPERT OPINION: Despite structural differences, all jurisdictions converge on core principles emphasizing product quality, long-term safety, and traceability.

However, Brazil faces unique multi-agency coordination requirements and infrastructural constraints that may delay national deployment. Global evidence indicates that strengthening GMP facilities, analytical validation strategies, and harmonized regulatory processes, particularly for academic and point-of-care manufacturing, will be crucial to broaden access and sustain innovation in CAR-T therapies. CAR-T cell therapy is a novel treatment that utilizes a patient s own immune cells to recognize and target cancer cells for destruction.

While it has transformed the care of some blood cancers, its use is still limited worldwide due to its complexity and high production costs, as well as varying regulations among countries regarding the testing and approval of these therapies. This article examines the regulation of CAR-T treatments in Brazil in comparison to the United States and the European Union.

In all three locations, health agencies require strong evidence that CAR-T cells are manufactured safely, function as intended, and do not cause long-term harm, which includes strict control over laboratory processes, equipment, and tests used in the manufacturing of the therapy.

We also discuss special programs that allow patients with severe or rare diseases to receive CAR-T therapy even before it is fully approved. Real-life examples from recent clinical studies demonstrate how these pathways can benefit patients who have no other treatment options.

Overall, the review highlights that although countries differ in their regulations, they share the same goals: protecting patient safety and ensuring the production of high-quality CAR-T products. Strengthening laboratory infrastructure and simplifying regulatory pathways, particularly in countries like Brazil, will enable more patients to benefit from this life-saving therapy.